Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xiaowu Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5792-9839; OpenAlex author ID A5100605525, A5123919161. Sources: OpenAlex.

Their work

Papers
38 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2019: 6 papers · 2020: 3 papers · 2021: 9 papers · 2022: 3 papers · 2023: 4 papers · 2024: 7 papers · 2025: 3 papers · 2026: 3 papers

Papers 38

  1. Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB. Co-author DOI 10.1007/s13402-026-01164-y↗
  2. SUZ12 promotes pancreatic ductal adenocarcinoma progression and chemoresistance by epigenetically silencing NCOA4-induced ferroptosis. Co-author DOI 10.3724/abbs.2025215↗
  3. DUSP5 regulates ferroptosis in pancreatic cancer by down-regulating SCD1 expression via ERK1/2. Co-author DOI 10.3724/abbs.2026105↗
  4. Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41401-025-01477-y↗
  5. NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine. Co-author DOI 10.3724/abbs.2024221↗
  6. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. Co-author DOI 10.3724/abbs.2025111↗
  7. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Co-author DOI 10.1002/mc.23645↗
  8. Evaluating the efficacy of laparoscopic radical antegrade modular pancreatosplenectomy in selected early-stage left-sided pancreatic cancer: a propensity score… Last author DOI 10.1007/s00464-024-10868-x↗
  9. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217197↗
  10. PITX2 functions as a transcription factor for GPX4 and protects pancreatic cancer cells from ferroptosis. Co-author DOI 10.1016/j.yexcr.2024.114074↗
  11. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Co-author DOI 10.1111/cpr.13694↗
  12. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… Last author DOI 10.1186/s12957-023-03277-2↗
  13. IL15RA-STAT3-GPX4/ACSL3 signaling leads to ferroptosis resistance in pancreatic cancer. Co-author DOI 10.3724/abbs.2024153↗
  14. Nuclear receptor coactivator 6 (NCoA6) promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1002/cam4.6427↗
  15. Hernandezine induces autophagic cell death in human pancreatic cancer cells via activation of the ROS/AMPK signaling pathway. Co-author DOI 10.1038/s41401-022-01006-1↗
  16. SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD. Co-author DOI 10.1186/s12935-023-02899-6↗
  17. PITX2 in pancreatic stellate cells promotes EMT in pancreatic cancer cells via the Wnt/β-catenin pathway. Co-author DOI 10.3724/abbs.2023118↗
  18. A multimodal model fusing multiphase contrast-enhanced CT and clinical characteristics for predicting lymph node metastases of pancreatic cancer. Co-author DOI 10.1088/1361-6560/ac858e↗
  19. A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression. Co-author DOI 10.3724/abbs.2022111↗
  20. [Effect of laparoscopic surgery for pancreatic cancer after neoadjuvant chemotherapy]. Co-author DOI 10.3760/cma.j.cn112139-20210823-00389↗
  21. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  22. Organoid model: A new hope for pancreatic cancer treatment? Co-author DOI 10.1016/j.bbcan.2020.188466↗
  23. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  24. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.redox.2020.101807↗
  25. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Co-author DOI 10.1038/s41401-020-00584-2↗
  26. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Last author DOI 10.1093/abbs/gmab074↗
  27. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  28. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-0414↗
  29. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Co-author DOI 10.1186/s12935-021-02210-5↗
  30. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  31. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  32. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  33. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.03.024↗
  34. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Last author DOI 10.1111/cpr.12603↗
  35. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Last author DOI 10.1186/s12935-019-0767-4↗
  36. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1186/s12935-019-1025-5↗
  37. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Last author DOI 10.1186/s12964-019-0344-4↗
  38. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shunrong Ji · 26 shared papers, 2019–2025 · strength 3.60
  2. Xianjun Yu · 25 shared papers, 2019–2025 · strength 3.46
  3. Yi Qin · 25 shared papers, 2019–2025 · strength 3.42
  4. Qifeng Zhuo · 16 shared papers, 2020–2025 · strength 2.33
  5. Ye Zeng · 14 shared papers, 2019–2025 · strength 2.06
  6. Wensheng Liu · 17 shared papers, 2019–2024 · strength 1.95
  7. Wenyan Xu · 14 shared papers, 2019–2025 · strength 1.67
  8. Qiangsheng Hu · 15 shared papers, 2019–2023 · strength 1.60
  9. Zheng Zhang · 12 shared papers, 2019–2021 · strength 1.19
  10. Borui Li · 5 shared papers, 2024–2026 · strength 1.07
  11. Mengqi Liu · 9 shared papers, 2019–2021 · strength 0.93
  12. Qiqing Sun · 9 shared papers, 2019–2020 · strength 0.84
  13. Chenjie Zhou · 4 shared papers, 2022–2025 · strength 0.78
  14. Haidi Chen · 4 shared papers, 2021–2025 · strength 0.75
  15. Zheng Li · 3 shared papers, 2024–2026 · strength 0.67
  16. Zhiliang Wang · 3 shared papers, 2024–2026 · strength 0.64
  17. Di Wu · 3 shared papers, 2023–2025 · strength 0.59
  18. Changfeng Song · 4 shared papers, 2021–2023 · strength 0.58
  19. Yue Zhang · 3 shared papers, 2022–2024 · strength 0.52
  20. Wuhan Yang · 2 shared papers, 2025–2026 · strength 0.51
  21. Haifeng Hu · 3 shared papers, 2021–2024 · strength 0.49
  22. Xuemin Chen · 3 shared papers, 2022–2023 · strength 0.48
  23. Ye Zeng · 4 shared papers, 2019–2021 · strength 0.43
  24. Mengqi Liu · 3 shared papers, 2019–2024 · strength 0.42
  25. Xin Wang · 2 shared papers, 2023–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.